WARNER-LAMBERT ACCUPRIL SALES UP 37% TO $312 MIL., LEADING Rx SALES GROWTH IN 1995; CARDINAL REPORTS SUBSTANTIALLY IMPROVED GROSS MARGINS
Warner-Lambert's 1995 pharmaceutical sales were fueled by growth from the ACE inhibitor Accupril, which posted a sales gain of 37% and full-year revenues of $312 mil. Warner-Lambert reported Jan. 23 that overall 1995 sales worldwide increased 10% to $7.04 bil. Sales for the year included a 7% unit volume gain, the company noted. Earnings for the year increased 7% to $740 mil. and included a third quarter, pre-tax charge of $117 mil. from the sale of the PRO toothbrush business.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth